13 terminated. 13 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Terminated 13 |
| Phase 2 | 3 | Terminated 3 |
Follow Hyperlipidemias: new trials by email Literature Review of Hyperlipidemias trials Research Report on Hyperlipidemias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of LY3875383 in Healthy Participants and Participants With Hypertriglyceridemia LY3875383, Placebo - Hypertriglyceridemia | Phase 1 | Terminated | Eli Lilly and Company | 41 | 2022-11-14 | 2025-06-04 |
| A First in Human Study of STT-5058, an Antibody That Binds ApoC3 STT-5058, Placebo - Hypertriglyceridemia | Phase 1 | Terminated | Staten Biotechnology BV | 93 | 2020-05-26 | 2023-01-23 |
| A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH) AAV directed hLDLR gene therapy - Homozygous Familial Hypercholesterolemia (HoFH) | Phase 1 / Phase 2 | Terminated | REGENXBIO Inc. | 9 | 2016-03-01 | 2023-07-13 |
| Pharmacokinetic and Pharmacodynamic Study of Bococizumab Alone and When Combined With Recombinant Human Hyaluronidase Cohort 1: bococizumab 150 mg + rHuPH20, Cohort 2: bococizumab 300 mg, Cohort 3: bococizumab 300 mg + rHuPH20 - Healthy, Hypercholesterolemia | Phase 1 | Terminated | Pfizer | 60 | 2016-02-01 | 2016-10-21 |
| Single Dose Study of PF-06815345 in Healthy Subjects PF-06815345, Placebo - Hypercholesterolemia | Phase 1 | Terminated | Pfizer | 25 | 2015-11-01 | 2018-09-28 |
| PK Study of YH22189 FDC Compared to Combination of Telmisartan/Amlodipine and Rosuvastatin YH22189, Twynsta 80/10mg, Crestor 20mg - Hypertension, Hyperlipidemia | Phase 1 | Terminated | Yuhan Corporation | 123 | 2015-11-01 | 2017-02-01 |
| A Safety Study of BMS-852927 in Subjects With Hypercholesterolemia BMS-852927, Placebo - Hypercholesterolemia | Phase 1 | Terminated | Bristol-Myers Squibb | 97 | 2012-11-01 | 2013-08-05 |
| A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158) MK-0524A - Hypercholesterolemia, Familial, Heterozygous Familial Hypercholesterolemia | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 10 | 2012-06-01 | 2015-11-03 |
| Multiple Ascending Dose Study of SPC5001 in Treatment of Healthy Subjects and Subjects With FH SPC5001, Saline 0.9% - Hypercholesterolemia | Phase 1 | Terminated | Santaris Pharma A/S | 24 | 2011-05-01 | 2011-11-22 |
| Safety Study of BMS-844421 for Treatment of Hypercholesterolemia BMS-844421, 0.9% sodium chloride injection solution - Atherosclerosis, Hypercholesterolemia | Phase 1 | Terminated | Bristol-Myers Squibb | 40 | 2010-04-01 | 2011-01-26 |
| IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia Atorvastatin - HIV Infections, Hyperlipidemia | Phase 1 / Phase 2 | Terminated | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | 28 | 2009-08-01 | 2016-04-06 |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol PRO-040201, Placebo - Hypercholesterolemia | Phase 1 | Terminated | Arbutus Biopharma Corporation | 23 | 2009-06-01 | 2010-01-22 |
| Study of 3,5-Diiodothyropropionic Acid (DITPA) in Hypercholesterolemic Patients 3,5-Diiodothyropropionic acid (DITPA) therapy - Hypercholesterolemia | Phase 1 / Phase 2 | Terminated | Johns Hopkins University | 60 | 2006-04-01 | 2013-04-02 |
Hypercholesterolemia (7) · Atherosclerosis (2) · Hyperlipoproteinemia Type II (2) · Hypertriglyceridemia (2) · Cardiovascular Diseases (1) · Coronary Artery Disease (1) · Dyslipidemias (1) · Genetic Diseases, Inborn (1) · HIV Infections (1) · Homozygous Familial Hypercholesterolemia (1) · Hypertension (1) · Metabolic Diseases (1) · Rare Diseases (1)
Lipid Metabolism Disorders (13) · Nutritional and Metabolic Diseases (13) · Dyslipidemias (12) · Metabolic Diseases (12) · Vascular Diseases (4) · Arterial Occlusive Diseases (3) · Arteriosclerosis (3) · Cardiovascular Diseases (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Hyperlipoproteinemias (2) · Lipid Metabolism, Inborn Errors (2) · Metabolism, Inborn Errors (2) · Blood-Borne Infections (1) · Communicable Diseases (1)
3,5-diiodothyropropionic acid (1) · Amlodipine (1) · Atorvastatin (1) · MK-0524 (1) · Niacin (1) · Rosuvastatin Calcium (1) · SPC5001 (1) · Sodium Chloride (1) · Telmisartan (1) · Therapeutics (1) · telmisartan amlodipine combination (1)
Bristol-Myers Squibb (2) · Pfizer (2) · Arbutus Biopharma Corporation (1) · Eli Lilly and Company (1) · International Maternal Pediatric Adolescent AIDS Clinical Trials Group (1) · Johns Hopkins University (1) · Merck Sharp & Dohme LLC (1) · REGENXBIO Inc. (1) · Santaris Pharma A/S (1) · Staten Biotechnology BV (1) · Yuhan Corporation (1)
United States (4) · Belgium (2) · Canada (2) · Germany (2) · Netherlands (2) · Italy (1) · Singapore (1) · South Korea (1) · United Kingdom (1)
Ann Melvin, MD (1) · Annabelle Rodriguez, MD (1) · Douglas Logan, MD (1) · Koos Burggraaf, MD PhD (1) · Marilyn Crain, MD, MPH (1)
2015 (2), 2009 (1), P01HL059407 (1), U01AI068632 (1)